BCL2 and melanoma: Although SOX10 immunostaining and molecular testing were not performed due to institutional limitations and lack of access to advanced diagnostic resources, the diagnosis of MPNST was supported by compatible histological features and a broad immunohistochemical panel, including markers such as BCL2, CD34, CDX2, P63, CK7, and CK20, and a pan melanoma panel.